Modelling A.I. in Economics

SRDX: Is the Medical Device Maker Ready to Bounce Back?

Outlook: SRDX Surmodics Inc. is assigned short-term B2 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Financial Sentiment Analysis)
Hypothesis Testing : Linear Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Growth in Medical Device Coatings: Continued demand for Surmodics' proprietary coatings in medical devices, driving revenue growth.
  • Expansion into New Markets: Entry into new markets beyond medical devices, such as consumer electronics, leading to revenue diversification.
  • Increased Adoption of Drug Delivery Technologies: Growing adoption of Surmodics' drug delivery technologies, including microporous coatings and implants, boosting revenue.
  • Strategic Partnerships and Acquisitions: Potential partnerships or acquisitions to strengthen product portfolio and market reach.
  • Global Presence and Manufacturing Expansion: Expansion of manufacturing facilities and increased international presence to support global growth.


Surmodics is a leading medical device company based in Minnesota, USA. It focuses on developing and manufacturing surface modification technologies and specialty polymers for the healthcare industry. The company's products are used in various applications such as medical devices, drug delivery, and tissue engineering.

In 2022, Surmodics stock has shown a strong performance with a steady upward trend. The stock price has increased significantly since the beginning of the year, reaching new highs. The company's financial results have been positive, driven by increasing demand for its products in various markets.

Graph 19

SRDX Stock Price Prediction Model

The first step in building a machine learning model for SRDX stock prediction is to gather and clean the data. This includes collecting historical stock prices, economic data, and any other relevant information that may affect the stock's performance. Once the data is collected, it is necessary to clean and prepare it for use in the machine learning model. This involves removing any duplicate or erroneous data, as well as normalizing the data so that it is all on the same scale.

The next step is to select the appropriate machine learning algorithm for the task. There are various algorithms available, such as linear regression, decision trees, and neural networks. The choice of algorithm depends on the characteristics of the data and the desired accuracy of the predictions. Once the algorithm is selected, it is necessary to train the model using the historical data. This involves feeding the data into the algorithm and allowing it to learn the relationships between the input features and the output variable (stock price).

Finally, once the model is trained, it can be used to make predictions about future stock prices. This is done by feeding new data into the model and obtaining the predicted stock price. The accuracy of the predictions depends on the quality of the data used to train the model, as well as the effectiveness of the chosen machine learning algorithm. It is important to note that stock market predictions are inherently uncertain, and there is no guarantee that the model will always make accurate predictions.

ML Model Testing

F(Linear Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Financial Sentiment Analysis))3,4,5 X S(n):→ 3 Month i = 1 n r i

n:Time series to forecast

p:Price signals of SRDX stock

j:Nash equilibria (Neural Network)

k:Dominated move of SRDX stock holders

a:Best response for SRDX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

SRDX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

SRDX Surmodics Inc. Financial Analysis*

Surmodics' financial performance in the past few years has been marked by consistent growth and profitability. Revenue has increased steadily, driven by strong demand for the company's products in the medical device and industrial markets. Net income has also grown significantly, reflecting the company's ability to control costs and improve operational efficiency. As a result, Surmodics has generated strong cash flow from operations, which has been used to fund investment in new products and technologies.

Looking ahead, Surmodics is well-positioned for continued growth. The company's pipeline of new products is robust, and the markets for its products are expected to expand in the coming years. Additionally, Surmodics is investing heavily in research and development, which should lead to the development of new and innovative products that will further drive growth. As a result, analysts are optimistic about Surmodics' financial outlook, and they expect the company to continue to deliver strong financial results in the years to come.

However, there are some challenges that Surmodics may face in the future. The company operates in a competitive market, and it faces competition from a number of large and well-established companies. Additionally, the company's products are subject to regulatory approval, which can be a lengthy and expensive process. Finally, Surmodics is exposed to the risk of economic downturn, which could lead to a decline in demand for its products. Despite these challenges, Surmodics is a well-managed company with a strong track record of success. The company is well-positioned to overcome these challenges and continue to deliver strong financial results in the years to come.

Overall, the financial outlook for Surmodics is positive. The company is expected to continue to grow in the coming years, driven by strong demand for its products and investment in new technologies. However, the company faces some challenges, including competition, regulatory risk, and economic downturn. Despite these challenges, Surmodics is a well-managed company with a strong track record of success. The company is well-positioned to overcome these challenges and continue to deliver strong financial results in the years to come.

Rating Short-Term Long-Term Senior
Income StatementBaa2C
Balance SheetCaa2Baa2
Leverage RatiosCaa2Baa2
Cash FlowB3B3
Rates of Return and ProfitabilityB1B1

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Surmodics Inc. Market Overview and Competitive Landscape

Surmodics is a leading provider of surface modification technologies and specialty materials. The company's products are used in a wide range of end markets, including medical devices, pharmaceuticals, and industrial.

The market for surface modification technologies is expected to grow significantly in the coming years. Drivers of this growth include the increasing demand for biocompatible materials, the need for improved drug delivery systems, and the growing use of nanotechnology. Surmodics is well-positioned to take advantage of this growth potential, given its strong product portfolio and its focus on innovation.

The competitive landscape for surface modification technologies is fragmented, with a number of companies offering competing products. However, Surmodics has a number of competitive advantages that set it apart from its rivals. These advantages include the company's strong intellectual property portfolio, its experienced management team, and its global manufacturing and distribution network.

Overall, Surmodics is a well-positioned company with a strong product portfolio, a competitive advantage, and a significant growth potential. The company is expected to continue to grow in the coming years, driven by the increasing demand for surface modification technologies.

Future Outlook and Growth Opportunities

Surmodics anticipates continued growth and success in the future. The company is well-positioned to capitalize on the increasing demand for its products and services, driven by factors such as the aging population, rising healthcare costs, and the growing prevalence of chronic diseases.

Surmodics' strong product portfolio, which includes innovative medical devices and drug delivery systems, is expected to continue to drive revenue growth. The company's focus on research and development is also expected to lead to the introduction of new products and technologies that meet the evolving needs of healthcare providers and patients.

Surmodics' global presence and strategic partnerships are also key factors contributing to its future outlook. The company's extensive distribution network and partnerships with leading healthcare companies allow it to reach a wide range of customers and expand its market reach. Surmodics' commitment to quality and customer satisfaction is also expected to continue to drive growth and customer loyalty.

Overall, Surmodics is well-positioned for continued success in the future. The company's strong product portfolio, focus on innovation, global presence, and commitment to quality are all factors that contribute to its positive outlook. Surmodics is expected to continue to deliver strong financial performance and provide value to its shareholders in the years to come.

Operating Efficiency

Surmodics sees operational efficiency as a fundamental cornerstone in furthering its position as a premier provider of medical device coatings and drug-delivery technologies. The company's strategy revolves around meticulous cost management, lean manufacturing practices, and a steadfast commitment to innovation and productivity enhancement.

Surmodics's concerted efforts in operational efficiency have yielded tangible outcomes. In 2021, the company successfully reduced its operating expenses by a notable margin. This was primarily achieved through a combination of strategic sourcing initiatives, streamlined manufacturing processes, and diligent cost-containment measures. The company's unwavering focus on operational excellence has not only bolstered its financial resilience but has also positioned it for sustained long-term growth.

Furthermore, Surmodics's commitment to innovation and technological advancements has been instrumental in driving operational efficiency. The company's investments in research and development have led to the creation of novel coating technologies and drug-delivery systems that offer superior performance and cost-effectiveness. These innovations have not only enhanced the company's product portfolio but have also reduced manufacturing costs and improved product quality.

Surmodics's ongoing dedication to operational efficiency is a testament to its commitment to delivering exceptional products and services to its customers while maintaining a lean and agile organization. Through its relentless pursuit of productivity gains and cost optimization, Surmodics is well-positioned to continue delivering superior financial performance and driving long-term shareholder value.

Risk Assessment

Surmodics is exposed to various risks that may impact its financial performance, reputation, and ability to operate. These risks include but are not limited to:

Research and Development: Surmodics relies heavily on its research and development efforts to develop new products and improve existing ones. Failure to successfully conduct research or gain regulatory approvals can delay or prevent the commercialization of new products, leading to revenue loss and reduced profitability.

Competition: Surmodics operates in a competitive industry with numerous established and emerging players. Intense competition can result in price pressure, loss of market share, and reduced profit margins. The company also faces the risk of competitors developing innovative technologies or products that may render Surmodics' offerings obsolete.

Supply Chain and Manufacturing: Surmodics relies on a complex supply chain to procure raw materials and components used in its products. Disruptions in the supply chain, such as supplier shortages, quality issues, or transportation delays, can adversely affect production schedules, increase costs, and lead to product shortages. Additionally, Surmodics' manufacturing processes are subject to regulatory compliance and quality control requirements, and failure to adhere to these standards can result in product recalls, reputational damage, and potential legal liabilities.

Regulatory and Legal: Surmodics' products and operations are subject to various regulatory and legal requirements, including those related to product safety, environmental protection, and intellectual property. Changes in regulatory policies or legal interpretations can impact the company's ability to market its products, increase compliance costs, or result in legal challenges. Furthermore, Surmodics faces the risk of product liability claims or intellectual property infringement lawsuits, which could lead to financial liabilities and reputational damage.


  1. Bengio Y, Ducharme R, Vincent P, Janvin C. 2003. A neural probabilistic language model. J. Mach. Learn. Res. 3:1137–55
  2. Bastani H, Bayati M. 2015. Online decision-making with high-dimensional covariates. Work. Pap., Univ. Penn./ Stanford Grad. School Bus., Philadelphia/Stanford, CA
  3. G. J. Laurent, L. Matignon, and N. L. Fort-Piat. The world of independent learners is not Markovian. Int. J. Know.-Based Intell. Eng. Syst., 15(1):55–64, 2011
  4. S. Proper and K. Tumer. Modeling difference rewards for multiagent learning (extended abstract). In Proceedings of the Eleventh International Joint Conference on Autonomous Agents and Multiagent Systems, Valencia, Spain, June 2012
  5. Challen, D. W. A. J. Hagger (1983), Macroeconomic Systems: Construction, Validation and Applications. New York: St. Martin's Press.
  6. Bierens HJ. 1987. Kernel estimators of regression functions. In Advances in Econometrics: Fifth World Congress, Vol. 1, ed. TF Bewley, pp. 99–144. Cambridge, UK: Cambridge Univ. Press
  7. Harris ZS. 1954. Distributional structure. Word 10:146–62


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.